Inovio Biomedical (Inovio) has reported interim safety and immunogenicity data from its therapeutic cervical cancer vaccine (VGX-3100) trial. VGX-3100 is a DNA vaccine targeting the E6 and E7
Nutra Pharma has completed the first production run of Cobroxin and has successfully released it for final distribution. The company expects Cobroxin to be available for sale as
Santhera, a Swiss specialty pharmaceutical company focused on orphan neuromuscular diseases, has closed the acquisition of Turku, Finland-based Oy Juvantia Pharma. The closing of the transaction triggers a
Australia-based Cancer Therapeutics CRC (CTx) has collaborated with Duke University, North Carolina, USA (Duke) for the discovery and development of new drugs to treat many forms of cancer,
Kureha Corporation and Mitsubishi Tanabe Pharma have entered into an agreement, under which Kureha shall grant Mitsubishi Tanabe a license to market chronic renal failure drug Kremezin in
DiagnoCure has signed an exclusive agreement with Lab21 for the promotion, marketing and selling of its Previstage GCC Colorectal Cancer Staging Test in the UK and Ireland. Reportedly,
MediGene has received feedback from the UK MHRA (Medicines and Healthcare products Regulatory Agency) regarding the in-vitro studies conducted with the drug candidate RhuDex for the treatment of
Seattle-based biotechnology company Theraclone Sciences has entered into a multi-year research and development agreement with Zenyaku Kogyo, a pharmaceutical company based in Tokyo. The collaboration will use Theraclone’s
Seattle Genetics has discontinued the SeaGen MARINER phase IIb clinical trial based on a determination that the trial would be unlikely to meet its primary endpoint of complete
Sigma-Aldrich and Sangamo BioSciences have announced the expansion of their existing license agreement to include the exclusive rights to develop and distribute zinc finger DNA binding protein (ZFP)-modified
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.